Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03400826 · ClinicalTrials.gov registry record · Phase 2

Effects of Simvastatin on Uterine Leiomyoma Size

A Phase 2 study of Leiomyoma and Fibroid Uterus, sponsored by Johns Hopkins University.

Recruiting
Registry status
Phase 2
Development phase
60
Enrollment target
1
Study location

NCT03400826 is a Phase 2 study of Leiomyoma and Fibroid Uterus that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 60 participants, below the 98-participant average among 8 other Leiomyoma trials with a reported enrollment target (39% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03400826, a Phase 2 study of Leiomyoma and Fibroid Uterus, is actively recruiting participants, sponsored by Johns Hopkins University.

RECRUITING
Registry status
Phase 2
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

The study aims to study the effect of simvastatin on the size of uterine fibroids.

Interventions

  • DRUG Simvastatin 40mg
  • DRUG Placebo 40 mg

Study Locations (1)

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2018-08-20
Est. Completion 2026-07-31
Phase Phase 2

Sponsor

Johns Hopkins University

1,448 total trials

What the Registry Record Tells You About NCT03400826

The ClinicalTrials.gov registry entry for NCT03400826 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 98-participant average among 8 other Leiomyoma trials with a reported enrollment target (39% lower). The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Leiomyoma appearing as the primary indexed condition, and to 2 interventions - of which Simvastatin 40mg is the first listed.

NCT03400826 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT03400826 about?

NCT03400826 is a clinical study titled "Effects of Simvastatin on Uterine Leiomyoma Size". The study aims to study the effect of simvastatin on the size of uterine fibroids.

What is the current status of trial NCT03400826?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2018-08-20. Estimated completion is 2026-07-31.

What conditions does trial NCT03400826 study?

This clinical trial studies the following conditions: Leiomyoma, Fibroid Uterus, Leiomyoma, Uterine, Fibroid Tumor, Fibromyoma.

What interventions are being tested in trial NCT03400826?

The interventions under investigation include: Simvastatin 40mg (DRUG), Placebo 40 mg (DRUG).

Who is sponsoring clinical trial NCT03400826?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03400826 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Leiomyoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.